Bolt Biotherapeutics Inc expected to post a loss of $6.45 a share - Earnings Preview

Bolt Biotherapeutics

08/08/2025 14:51

Bolt Biotherapeutics Inc BOLT.OQ BOLT.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Redwood City California-based  company is expected to report a 35.7% decrease in revenue to $819.75 thousand from $1.28 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Bolt Biotherapeutics Inc is for a loss of $6.45 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $20.00, about 71.8% above its last closing price of $5.64

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-7.14
-7.25
-5.80
Beat
20
Dec. 31 2025
-7.60
-7.60
Met
0
Sep. 30 2024
-6.71
-7.05
-8.00
Missed
-13.5​
Jun. 30 2024
-10.44
-9.60
-9.20
Beat
4.2
​​Mar. 31 2024
-9.98
-10.20
-5.60
Beat
45.1
Dec. 31 2023
-8.84
-9.63
-9.40
Beat
2.4​
Sep. 30 2023
-9.96
-10.00
-8.60
Beat
14
Jun. 30 2023
-9.93
-9.73
-9.60
Beat
1.4

This summary was machine generated August 8 at 13:51 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)